MPLT vs NBIX
MPLT: MapLight Therapeutics is a clinical-stage biopharmaceutical company developing circuit-specific therapies for serious central nervous system disorders, led by its flagship M1/M4 muscarinic agonist program. NBIX: A neuroscience-focused biopharmaceutical company commercializing specialized treatments for neurological and endocrine disorders while advancing a diverse pipeline of therapeutic modalities.
Side-by-side fundamentals
| Metric | MPLT | NBIX | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $9.15 | $141.25 | |
| Market cap | $388M | $14.4B | |
| P/E as of 2026-10-08 | n/a | 20.71 | |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2025 | n/a | 0.47 | |
| Net margin FY2025, SEC XBRL | n/a | +16.7% | |
| Operating margin FY2025, SEC XBRL | n/a | +21.6% | |
| ROE FY2025, SEC XBRL | -35.2% | +14.7% | NBIX higher |
| ROA FY2025, SEC XBRL | -33.6% | +10.3% | NBIX higher |
| Debt / equity as of 2026-09-03 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-09-03 | n/a | +34.4% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +24.3% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.55 | 0.78 | |
| 1-year return as of 2026-10-08 close | n/a | +1.6% |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.